GlaxoSmithKline PLC is reviewing strategic options for its European prescription pharmaceuticals business as part of a new £1.5 billion "major change" program that will include the adoption of new manufacturing and R&D technologies and the simplification of supply chain processes.
It seems that nothing is being ruled in or out for consideration in a bid to maximize the value of...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?